Today, December 16, 2024, on an investor call and in a press release, Larimar Therapeutics shared data from their ongoing long-term open label extension study and progress across the nomlabofusp program for Friedreich’s ataxia.
You can read the full press release or listen to the webcast by clicking the buttons below.